Literature DB >> 21046269

Survival implications of cervical lymphadenectomy in patients with medullary thyroid cancer.

Emad Kandil1, Marta M Gilson, Haytham H Alabbas, Anthony P Tufaro, Alan Dackiw, Ralph P Tufano.   

Abstract

BACKGROUND: The relationship between extent of cervical lymphadenectomy along with the number of involved lymph nodes (LNs) removed and overall survival has not been well documented in patients with medullary thyroid carcinoma (MTC). This study investigates whether the overall number of LNs removed and the number of metastatic LNs are independent prognostic factors for overall survival.
METHODS: Data from patients with MTC in the Surveillance, Epidemiology, and End Results (SEER) registry database were examined. After categorizing the study population based on the number of overall LNs examined and the number of metastatic LNs, survival estimates were compared. The total number of examined LNs and their histopathological status were analyzed for their prognostic value in estimating overall survival.
RESULTS: 593 patients were included in this study. Those with all negative LNs had the best overall survival; those with LNs examined and at least one positive LN had worst overall survival (p < 0.0001). The total number of examined LNs for both groups with negative and positive LNs was not associated with improved survival outcome (p = 0.41). In node-positive patients, each additional positive LN was significantly associated with an increase in overall mortality [hazard ratio (HR) = 1.05, 95% confidence interval (CI) = 1.02-1.08].
CONCLUSIONS: Cervical LN metastases conferred an independent risk for worse survival rate in MTC. Cervical lymphadenectomy is important for staging and regional disease control, however the extent of lymph node dissection, the overall number of lymph nodes removed along with removal of an increased number of involved lymph nodes do not confer a survival advantage. Future prospective studies are needed.

Entities:  

Mesh:

Year:  2010        PMID: 21046269     DOI: 10.1245/s10434-010-1363-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  11 in total

1.  Treating medullary thyroid cancer in the age of targeted therapy.

Authors:  Maria E Cabanillas; Mimi I Hu; Camilo Jimenez; Elizabeth G Grubbs; Gilbert J Cote
Journal:  Int J Endocr Oncol       Date:  2014

2.  Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years.

Authors:  Reese W Randle; Courtney J Balentine; Glen E Leverson; Jeffrey A Havlena; Rebecca S Sippel; David F Schneider; Susan C Pitt
Journal:  Surgery       Date:  2016-11-11       Impact factor: 3.982

3.  Aggressive medullary thyroid cancer, an analysis of the Irish National Cancer Registry.

Authors:  P Lennon; S Deady; N White; D Lambert; M L Healy; A Green; J Kinsella; C Timon; J P O' Neill
Journal:  Ir J Med Sci       Date:  2016-04-15       Impact factor: 1.568

4.  Predictive factors that influence the course of medullary thyroid carcinoma.

Authors:  Kalliopi Pazaitou-Panayiotou; Alexandra Chrisoulidou; Stylianos Mandanas; Konstantinos Tziomalos; Eleni Doumala; Frideriki Patakiouta
Journal:  Int J Clin Oncol       Date:  2013-07-06       Impact factor: 3.402

5.  Surgical selection and prognostic analysis in patients with unilateral sporadic medullary thyroid carcinoma.

Authors:  Jinming Zhang; Pengfei Gu; Dongmei Huang; Jingzhu Zhao; Xiangqian Zheng; Ming Gao
Journal:  Langenbecks Arch Surg       Date:  2022-06-24       Impact factor: 3.445

6.  Prognostic value of LODDS in medullary thyroid carcinoma based on competing risk model and propensity score matching analysis.

Authors:  Zhe Xu Cao; Xin Weng; Jiang Sheng Huang; Xia Long
Journal:  Updates Surg       Date:  2022-07-12

Review 7.  [Surgical therapy for thyroid gland malignancies].

Authors:  P E Goretzki; K Schwarz; B Lammers
Journal:  HNO       Date:  2013-01       Impact factor: 1.284

8.  Are there disparities in the presentation, treatment and outcomes of patients diagnosed with medullary thyroid cancer?-An analysis of 634 patients from the California Cancer Registry.

Authors:  Christine Cox; Yingjia Chen; Rosemary Cress; Alison M Semrad; Thomas Semrad; Jessica E Gosnell; Michael J Campbell
Journal:  Gland Surg       Date:  2016-08

9.  Histology-proven recurrence in the lateral or central neck after systematic neck dissection for medullary thyroid cancer.

Authors:  Andreas Machens; Kerstin Lorenz; Henning Dralle
Journal:  Endocrine       Date:  2018-06-05       Impact factor: 3.633

10.  Extent of surgery in clinically evident but operable MTC - when is central and/or lateral lympadenectomy indicated?

Authors:  Oliver Gimm
Journal:  Thyroid Res       Date:  2013-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.